logo
logo

Tasca Therapeutics Raises $52 Million with Co-leaders Cure and Regeneron Ventures

Dec 11, 2024•7 months ago

Contract Type

partnership

BostonBiotechnology

Description

Tasca Therapeutics, a newly-minted small molecular inhibitor company, has raised $52 million in a Series A financing round. The round was co-led by Cure and Regeneron Ventures, with participation from Invus Group. The company plans to develop oncology drugs that target specific lipid-binding pockets on proteins.

Company Information

Company

Tasca Therapeutics

Location

349-351 NEWBURY STREET

Boston, Massachusetts, United States

About

Tasca Therapeutics is revolutionizing drug development by unlocking the potential of post-translational protein modifications. Using state-of-the-art chemical biology, computational approaches, and targeted inhibition at key metabolic nodes, Tasca tackles previously undruggable targets. Focused on hard-to-treat oncology indications, Tasca leverages its proprietary platform to develop innovative small-molecule drugs, paving the way for breakthroughs in cancer treatment.

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Related People